2026-04-27T01:59:28Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231532024-11-28T23:22:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16978col_20.500.12105_16982

00925njm 22002777a 4500 dc Martin, Maria C author Jurado, Aurora author Abad-Molina, Cristina author Orduna, Antonio author Yarce, Oscar author Navas, Ana M author Cunill Monjo, Vanesa author Escobar, Danilo author Boix, Francisco author Burillo-Sanz, Sergio author Vegas-Sanchez, Maria C author Jimenez-de Las Pozas, Yesenia author Melero, Josefa author Aguilar, Marta author Sobieschi, Oana Irina author Lopez-Hoyos, Marcos author Ocejo-Vinyals, Gonzalo author San Segundo, David author Almeida, Delia author Medina, Silvia author Fernández, Luis author Vergara, Esther author Quirant, Bibiana author Martinez-Caceres, Eva author Boiges, Marc author Alonso, Marta author Esparcia-Pinedo, Laura author Lopez-Sanz, Celia author Muñoz-Vico, Javier author Lopez-Palmero, Serafin author Trujillo, Antonio author Alvarez, Paula author Prada, Alvaro author Monzon, David author Ontanon, Jesus author Marco, Francisco M author Mora, Sergio author Rojo, Ricardo author Gonzalez-Martinez, Gema author Martinez-Saavedra, Maria T author Gil-Herrera, Juana author Cantenys-Molina, Sergi author Hernandez, Manuel author Perurena-Prieto, Janire author Rodriguez-Bayona, Beatriz author Martinez, Alba author Ocana, Esther author Molina, Juan author 2021-05-20 Background: One hundred fifty million contagions, more than 3 million deaths and little more than 1 year of COVID-19 have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 comorbidities such as hypertension or dyslipidaemia. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. Results: Concerning the characteristics of lockdown series, mild cases accounted for 14.4, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age > 60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6, CRP, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 and CD8 count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. IL-6, CRP and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 T-cell count below 535 cells/mu L, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. Conclusion Age and sex together with selected laboratory parameters on admission can help us predict COVID-19 severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown might affect the homogeneity of the data and the robustness of the results. Martin MC, Jurado A, Abad-Molina C, Orduna A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18(1):24. 1742-4933 https://hdl.handle.net/20.500.13003/19847 https://hdl.handle.net/20.500.12105/23153 34016150 10.1186/s12979-021-00237-w Immunity & Ageing 2-s2.0-85106896740 652608400001 L2012111015 Severe acute respiratory syndrome coronavirus 2 COVID-19 Immunosenescence Lockdown Immunity Renin-angiotensin-aldosterone system inhibitors Cut-off points Lymphocytes Area under the curve The age again in the eye of the COVID-19 storm: evidence-based decision making